Cutaneous angiosarcoma (CAS) is a rare soft tissue sarcoma with rapid growth and poor prognosis. We retrospectively analyzed the data of 18 patients with CAS who underwent 18 F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) at the initial visit to the Department of Dermatology, Okayama University Hospital from September 2006 to March 2016. In the univariate survival analysis, patients with high standardized uptake values (SUV max ) of the primary tumor showed significantly poorer prognosis than those with low SUV max . Early assessment of prognosis using PET/CT may predict patient survival and is useful in the selection of therapeutic strategies.
INTRODUCTION
Cutaneous angiosarcoma (CAS) is a rare and severe soft tissue sarcoma with a 5-year survival rate of 30-35%. [1] [2] [3] Recent studies have shown the effectiveness of taxane chemotherapy in the treatment of CAS. 4, 5 In addition, new anticancer or molecular-targeted agents, such as eribulin, trabectedin and pazopanib, have shown potential in improving the prognosis of patients with soft tissue sarcomas including CAS. 6 However, useful prognostic factors for CAS have not yet been identified. Therefore, early indicators of prognosis may improve patient survival.
18
F-Fluorodeoxyglucose (FDG) parallels glucose metabolism in the human body and is widely used in the imaging of malignant tumors. FDG positron emission tomography/computed tomography (PET/CT) has been increasingly used in the diagnosis, staging and management of malignancies such as soft tissue sarcomas. Several studies showed that a high standardized uptake value (SUV max ) during PET/CT is predictive of poor prognosis in patients with sarcomas. [7] [8] [9] In a similar manner, PET/CT could be used to predict prognosis in CAS. Here, we describe 18 patients with CAS in whom PET/CT was performed at the initial hospital visit. The prognostic values of four factors (age, sex, stage and SUV max ) were analyzed.
CASE REPORT
We examined patient records of the Department of Dermatology, Okayama University Hospital, and identified 18 consecutive CAS patients who underwent PET/CT at the initial hospital visit from September 2006 to March 2016 (Table 1) . PET/CT was performed at the Okayama Diagnostic Imaging Center. Skin biopsy confirmed the diagnosis of CAS in all patients. The mean age was 74 years and 12 patients were male. The median length of follow up was 18.0 months (range, 4.8-60.8). Two female patients had primary CAS of the leg or hip arising from chronic leg edema and were diagnosed with Stewart-Treves syndrome. The remaining 16 patients had CAS of the scalp. The patients were classified into three stages: stage I for those with limited, local cutaneous tumors; II for those with regional lymph node metastases; and III for those with distant metastases. 10 In Figure 1 of a 28-day cycle until disease progression. Eleven patients received PTX and four patients received DTX. The remaining three patients did not receive taxane because of advanced age or interstitial pneumonia. Eleven patients died due to CAS during the observation period. No death occurred due to other causes.
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics version 20.0 (SPSS, Chicago, IL, USA). Kaplan-Meier analysis was performed for age, sex, stage and SUV max of the primary tumor to evaluate patient survival. SUV max of the metastatic lesion in stage II and III patients was not used in this analysis. A log-rank test was used to compare survival curves. P < 0.05 was considered statistically significant.
Ethics
The ethics committee of the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, and Okayama University Hospital approved this study (epidemiologic study no. 954).
Results
We performed univariate analysis of all 18 patients for age, sex, stage and SUV max of the primary tumor using KaplanMeier curves. Median age (77 years) and SUV max (7.96) were used as cut-off values. As shown in Figure 2 , age and sex showed no significant differences in the log-rank test. Patients with metastases (stages II and III) had significantly poorer prognosis than those without (stage I) (Fig. 2a-c) . Furthermore, patients with high SUV max had significantly poorer prognosis (Fig. 2d ) than those with low SUV max .
DISCUSSION
In this study, we showed that SUV max of angiosarcoma primary lesions could potentially predict prognosis. There are several case reports on the use of PET/CT in angiosarcoma, [11] [12] [13] [14] but to the best of our knowledge, this is the first reported case series in which PET/CT use for CAS was systematically reviewed. Positron emission tomography/CT is a combined imaging modality in which PET scans generate functional information while CT scans generate morphological information. It has the advantage of generating quantitative information (SUV max ) compared with conventional CT. In Kaplan-Meier analysis, patients with high SUV max were observed to have poorer prognosis than those with low SUV max . In recent years, the SUV max of the primary tumor has been shown to be predictive of prognosis in sarcomas. [7] [8] [9] In two studies, multivariate analysis showed that SUV max was a statistically significant independent predictor of prognosis. 7, 9 Kubo et al. performed a meta-analysis of six studies, totaling 514 patients with bone and soft tissue sarcomas. In their analysis, they demonstrated that higher SUV max is predictive of a significantly shorter overall survival period compared with a lower SUV max . 8 However, in this present study, multivariate analysis
could not be performed because of the insufficient number of cases examined. The results of our study did, however,
show that the SUV max of primary CAS is predictive of prognosis, which was similar to that for other sarcomas. In recent years, novel therapeutic agents, such as eribulin, trabectedin and pazopanib, have been shown to potentially improve the prognosis of patients with soft tissue sarcomas. 5 However, Kitamura et al. have reported that pazopanib does not bring remarkable improvement in patients with CAS. 15 Thus, the benefits of novel agents for CAS are still controversial. An early assessment of prognosis using SUV max at the initial visit may be helpful for the selection of therapies among conventional taxane chemotherapy and newly developed therapies. 
